seeking alpha article makes it clear.fresinius is expected to ramp up omontys use.
You are absolutely correct. 20 million or 25 million in sales, what difference does it make at this juncture. It's being tested and evaluated in a limited number of patients and the results are very favorable. We all knew this and when, not if, FMS, and 4 of 5 medium size dialysis centers begin to ramp up omontys use, this stock will fly. Did you notice the stock price did not tank after the seeking alpha article appeared. This is not the time to sell, but to buy. If you want to call Q4 sales disappointing then I think it's already been baked into the price. I guess we'll see tomorrow.